Skip to content
Review Open access

Circulating tumor DNA in neoadjuvant therapy for solid tumors

Aug 2026 · Frontiers in Oncology · Vol 16 · 1 citation · 247 references
Medicine

TL;DR

How ctDNA is facilitating a shift towards more precise, dynamic, and individualized paradigms in neoadjuvant therapy for solid tumors is elucidated to optimize patient management and outcomes.

Abstract

Circulating tumor DNA (ctDNA), a core component of liquid biopsy, demonstrates significant potential in the field of neoadjuvant therapy for solid tumors. This review systematically examines the role of ctDNA across the pre-, intra-, and post-neoadjuvant treatment phases, with a focus on its value in predicting therapeutic efficacy, assessing early treatment response, detecting minimal residual disease (MRD), and monitoring for recurrence. By synthesizing the latest clinical research data and advancements in molecular detection technologies, this article aims to elucidate how ctDNA is facilitating a shift towards more precise, dynamic, and individualized paradigms in neoadjuvant therapy for solid tumors. Furthermore, it analyzes the current challenges and future directions for integrating ctDNA analysis into clinical practice to optimize patient management and outcomes. Throughout, clinically validated applications are explicitly distinguished from those that remain investigational, and key unresolved questions are highlighted.

Read PDF

Similar papers

Review Oct 2026

Feasibility and Accuracy of Circulating Tumor DNA (ctDNA) in Assessing Response to Chemotherapy, Prognostication, and Guiding Therapy in Ovarian Cancer: A Review of Literature and Future Directions

Current evidence supports ctDNA's role as a prognostic and molecular monitoring biomarker; however, routine clinical implementation should await robust prospective evidence demonstrating that ctDNA-guided therapeutic strategies improve clinically meaningful patient outcomes.

S. Tejas, S. Anusha · 0 citations
Review Open access Oct 2026

Circulating Tumor DNA Across the Patient Journey in Pancreatic Cancer: From Molecular Profiling to Dynamic Disease Monitoring

Background/Objectives: Circulating tumor DNA (ctDNA) provides molecular information at different stages of the pancreatic ductal adenocarcinoma (PDAC) patient journey, but its clinical value differs according to when and why it is measured. This narrative review examines ctDNA from diagnosis and molecular profiling thr...

Makoto Abue, Naoki Asano, Takanori Morikawa et al. · 0 citations
Open access Sep 2026

Circulating Tumor DNA for Customisation of Tumor Immunotherapy: Technology Advance and Clinical Evidence

Circulating tumour DNA (ctDNA) in blood is now used in a less invasive way to guide personalised cancer therapy. Several blood tests can be conducted on ctDNA to determine whether there is a distant spread of cancer cells, discover microscopic cancer cells remaining after surgery, and observe how the immune system resp...

Ya-Nan Chen · 0 citations
Review Oct 2026

Circulating tumor DNA in gynecologic oncology: moving from the present into the future.

PURPOSE OF REVIEW The use of circulating tumor DNA (ctDNA) offers a promising, minimally invasive alternative to tissue biopsies for real-time surveillance in gynecologic cancers. This review provides an overview of ctDNA technology, its clinical interpretation and foundational applications in oncology, as well as its...

Y. Chang, Yvonne G. Lin · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.